Slingshot members are tracking this event:
Allergan Receives FDA Approval of TEFLARO (ceftaroline fosamil) for Pediatric Patients
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
- TEFLARO is the First Branded IV Antibiotic Approved for Pediatric Patients in More Than a Decade -
Slingshot Insights Explained
May 31, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Teflaro, Antibiotic, Pediatric Patients, Ceftriaxone, Aztreonam, Vancomycin, Cefazolin, Staphylococcus Aureus, Ommunity-acquired Bacterial Pneumonia